Ferreira, Bruna Velosa <br/><br/>
How many JAK inhibitors in myelofibrosis?  [electronic resource] 

 -  Best practice & research. Clinical haematology  Jun 2014 
 - 187-95 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1532-1924 
<br/><br/><label>Standard No.: </label>10.1016/j.beha.2014.07.010  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Benzamides--therapeutic use<br/>Bridged-Ring Compounds--therapeutic use<br/>Drug Therapy, Combination<br/>Gene Expression<br/>Histone Deacetylase Inhibitors--therapeutic use<br/>Humans<br/>Janus Kinase 1--antagonists & inhibitors<br/>Janus Kinase 2--antagonists & inhibitors<br/>Mutation<br/>Nitriles<br/>Primary Myelofibrosis--drug therapy<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrazoles--therapeutic use<br/>Pyrimidines--therapeutic use